Abstract
The pharmacological properties of the 5-hydroxytryptamine (HT)1A receptor agonist (R)-3,4-dihydro-N-isopropyl-3-(N-isopropyl-N-propylamino)-2H-1-benzopyran-5-carboxamide (NAE-086) were examined with in vitro and in vivo techniques. Receptor binding studies demonstrated that NAE-086 was a high-affinity and selective 5-HT1A receptor ligand with aKi value of 4.5 nM in membranes from rat hippocampus. Of 32 other receptors examined NAE-086 had a modest affinity only for the 5-HT7 receptor (Ki = 240 nM). NAE-086 inhibited VIP-stimulated adenylyl cyclase activity in GH4ZD10 cells with 79% of the efficacy of 5-HT. This inhibition was blocked by the 5-HT1A receptor (and β-adrenoceptor) antagonist (−)alprenolol. A minor metabolite of NAE-086 in rats, (R)-3,4-dihydro-3-(N-isopropyl-N-propylamino)-2H-1-benzopyran-5-carboxamide had a similar receptor profile but had 17 times higher affinity for the 5-HT1A receptor (Ki = 0.26 nM). In vivo, NAE-086 induced all the typical effects of a 5-HT1A receptor agonist in rats: it decreased 5-HT synthesis (5-HTP accumulation) and 5-HT turnover (measured as the ratio of 5-hydroxyindoleacetic acid/5-HT), increased corticosterone secretion, induced the 5-HT1A syndrome (flat body posture and forepaw treading), inhibited the cage-leaving response, and caused hypothermia. All the responses mediated by postsynaptic 5-HT1A receptors were attenuated after single or repeated treatment of the rats with NAE-086. Simultaneously with the development of the tolerance to 5-HT1A receptor-mediated responses, 5-HT2A receptor-mediated responses were enhanced, as judged from the increased number of spontaneous and/or agonist [1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane]-induced wet-dog shake responses. The significance of this behavioral effect in relation to clinical observations is discussed.
Footnotes
-
↵1 Present address: AstraZeneca, 1800 Concord Pike, Wilmington, DE 19850.
-
↵2 Present address: Department of Pharmacology, Umeå University, S-901 87 Umeå, Sweden.
-
↵3 Present address: Acadia Pharmaceuticals, 3911 Sorrento Valley Blvd., San Diego, CA 92121.
- Abbreviations:
- 5-HT
- 5-hydroxytryptamine
- ANOVA
- analysis of variance
- CCK
- cholecystokinin
- DAMGO
- [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin
- DOI
- 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
- DOPA
- l-3,4-dihydroxyphenylalanine
- DPDPE
- [d-Pen2,d-Pen5]-enkephalin
- EEDQ
- 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline
- GABA
- γ-aminobutyric acid
- GH4ZD10
- rat pituitary tumor cells
- HPLC
- high-performance liquid chromatography
- 5-HIAA
- 5-hydroxyindoleacetic acid
- 5-HTP
- 5-hydroxytryptophan
- 8-OH-DPAT
- 8-hydroxy-2-(di-n-propylamino)tetralin
- NAE-084
- (S)-3,4-dihydro-N-isopropyl-3-(N-isopropyl-N-propylamino)-2H-1-benzopyran-5-carboxamide
- NAE-111
- (R)-3,4-dihydro-3-(N-isopropyl-N-propylamino)-2H-1-benzopyran-5-carboxamide
- NSD 1015
- 3-hydroxybenzylhydrazine dihydrochloride
- TBPS
- t-butylbicyclophosphorothionate
- VIP
- vasoactive intestinal polypeptide
- Received May 16, 2001.
- Accepted August 29, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|